A CME Activity
Click here to complete your registration.
If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.
DATES AND TIMES
Welcome and Introduction
Recognizing and Diagnosing HCM
Individualizing Management of HCM
Agents in Development to Treat HCM
Q&A Session and Activity Roundup
Hypertrophic cardiomyopathy (HCM) is the most common monogenic cardiovascular disorder. Mutations in the proteins encoding myofilament contractile components lead to a hypertrophied but nondilated left ventricle. Patients can have dyspnea, palpitations, chest pain, syncope, and exercise intolerance. In the past, HCM was thought to be rare, however better diagnostic imaging has led to increased recognition of the disease. Prospective studies have shown that current targeted management strategies, developed over the last 20 years, have reduced HCM-related morbidity and mortality. However, many patients with HCM experience diagnostic delays leading to belated treatment that has a large negative impact on patient quality of life.
The educational program Improving Hypertrophic Cardiomyopathy Outcomes: Early Diagnosis, Management, and Targeted Agents on the Horizon will review the recommended diagnostic testing to identify patients with HCM and the evidence-based guidelines for managing these patients and provide information about agents in development to manage HCM.
Martin S. Maron, MD
Assistant Professor of Medicine
Director, Hypertrophic Cardiomyopathy Center
Co-Director Cardiac MRI and CT
Tufts Medical Center
Ethan J. Rowin, MD
Associate Director, Hypertrophic Cardiomyopathy Center
Tufts Medical Center
The intended audience for this educational initiative is cardiologists, the clinicians responsible for the diagnosis and management of patients with hypertrophic cardiomyopathy.
At the conclusion of an activity, participants should be able to:
- Employ guideline recommendations to diagnose HCM in patients with clinical presentations that suggest the disease
- Develop evidence-based individualized treatment strategies for patients with HCM
- Assess the mechanism of action, efficacy, and safety of agents in development to treat HCM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education and Rockpointe. The Potomac Center for Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATION STATEMENT
The Potomac Center for Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit or the evaluation, please email email@example.com.
The Potomac Center for Medical Education (PCME) adheres to the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.
All persons in a position to control the content of a continuing medical education program provided by PCME are required to disclose any relevant financial relationships with any commercial interest to PCME as well as to learners. All conflicts of interest are identified and resolved by PCME in accordance with the Standards for Commercial Support in advance of delivery of the activity to learners.
Disclosures will be made known to the participants prior to the start of the activity.
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of approved uses.
To ensure your computer is compatible for the live event, please perform a system check by clicking on the link http://livewebcast.net/test or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer is compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.
- 1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
- Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
- 512 MB of RAM (1 GB recommended)
- Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
- For HTML Client - Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)
- 1.83 GHz Intel Core Duo or faster processor
- 512 MB RAM (1 GB recommended)
- Mac OS X 10.12, 10.13 and 10.14
- Mozilla Firefox, Apple Safari, Google Chrome
- For HTML Client - Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)
- The Adobe Connect app for iOS and Android requires Adobe Connect Server version 8.2 or later
- Some features may not be enabled in all Adobe Connect meetings if one is using an Adobe Connect Server older than version 9.4.2 (required for Custom pods)
- Google Android 4.4 or later
- Apple iOS: iOS 8.1.2 or later
DSL/cable (wired connection recommended)
INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME CREDIT
There is no fee for this activity. To receive credit, participants must register, view the live CME activity in its entirety, and then complete the post-test with a score of 70% or better and the evaluation. The estimated time for completion of this activity is 1 hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.
Jointly provided by the Potomac Center for Medical Education and Rockpointe
Supported by an educational grant from MyoKardia, Inc., a wholly owned subsidiary of Bristol Myers Squibb.